Revolutionizing C. difficile Prevention

• September 15, 2025
• SporeGen
• Latest News

A first-of-its-kind microbiome-based platform for C. difficile relapse prevention - proven, patent-protected, and ready for food & pharma partners.

SporeGen® receives GRAS Notice No. GRN 000905 from the FDA for its probiotic SG188

• June 10, 2020
• SporeGen
• Latest News

Ownership Assignment of Bacillus Strains from Royal Holloway, University of London

• February 13, 2017
• SporeGen
• Latest News

Collaborative agreement signed with FG-Systems

• November 04, 2015
• SporeGen
• Latest News

SporeGen^® signed a MOU with FG-Systems in Berlin to work together on developing new animal feed products, probiotics and animal vaccines.

Successful collaborative research grant funded by AAFC

• March 22, 2016
• SporeGen
• Latest News

SporeGen^® has been successful on a collaborative research grant focused on animal feeds and led by Dr T. Alexander (Lethbridge, Alberta) funded by Agriculture and Agri-Food Canada.